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3Abstract
Medium-chain length Polyhydroxyalkanoates (MCL-PHAs) have demonstrated exceptional 
properties for cardiac tissue engineering (CTE) applications. Despite prior work on MCL-
PHA/Polycaprolactone (PCL) blends, optimal scaffold production and use as an alternative 
delivery route for controlled release of seeded cardiac progenitor cells (CPCs) in CTE 
applications in vivo has been lacking. We present herein applicability of MCL-PHA/PCL (95/5 
wt%) blends fabricated as thin films with an improved performance compared to the neat 
MCL-PHA.
Polymer characterization confirmed the chemical structure and composition of the 
synthesized scaffolds, while thermal, wettability, and mechanical properties were also 
investigated and compared in neat and porous counterparts. In vitro cytocompatibility studies 
were performed using perfluorocrown-ether (PFCE)-nanoparticle-labeled murine cardiac 
progenitor cells (CPC), and studied using confocal microscopy and 19F MRS/MRI. Seeded 
scaffolds were implanted and studied in the post-mortem murine heart in situ, and in two 
additional C57BL/6 mice in vivo (using single-layered and double-layered scaffolds) and 
imaged immediately after and at 7 days post-implantation. 
Superior MCL-PHA/PCL scaffold performance has been demonstrated compared to MCL-
PHA through experimental comparisons of a) morphological data using scanning electron 
microscopy and b) contact angle measurements attesting to improved CPC adhesion, c) in 
vitro confocal microscopy showing increased SC proliferative capacity, d) mechanical testing 
that elicited good overall responses.
In vitro MRI results justify the increased seeding density, increased in vitro MRI signal, and 
improved MRI visibility in vivo, in the double-layered compared to the single-layered scaffolds. 
Histological evaluations (bright-field, cytoplasmic (Atto647) and nuclear (DAPI) stains) 
performed in conjunction with confocal microscopy imaging attest to CPC binding within the 
scaffold, subsequent release and migration to the neighboring myocardium, and to increased 
retention in the murine myocardium in the case of the double-layered scaffold.
Thus, MCL-PHA/PCL blends possess tremendous potential for controlled delivery of CPCs 
and for maximizing possible regeneration in myocardial infarction. 
41. Introduction
Stem cell (SC) delivery has been proposed and applied as a novel and promising therapeutic 
approach for cardiac disease1, 2, 3. However, to-this-date, there is continued speculation over 
its efficacy, given the disparity of published preclinical and clinical results4, 5, despite scientific 
evidence for the existence of paracrine effects associated with beneficial functional 
improvements in the infarcted myocardium6. Therefore, controlled SC administration and 
release still presents tremendous challenges towards a therapeutically successful cell 
engineering approach.
Polymer scaffolds have been introduced as a novel, biomimetic approach for administration 
and controlled release of viable SCs to the diseased myocardium7, ultimately aiming to 
replace scar tissue with engrafted healthy cells with pluripotent/multipotent capacity.
Historically, the earliest attempts for tissue regeneration date to the early 1970s with the use 
of grafts over the injured myocardium8. The first efforts to deliver cells within scaffolds were 
pioneered by Souren et al.9, while more recent attempts target the use of inducible pluripotent 
SCs10. 
To this-date, collective efforts in cardiac tissue engineering have employed natural and 
synthetic materials and have been tested with a multitude of SC types8, 11 in different hosts, 
including the mouse, rat, rabbit, pig, sheep, dog, and human8. The scaffold substrates have 
been synthesized using materials, such as collagen, fibrin, chitosan, alginate12, hyaluronic 
acid, gelatin, matrigel, decellularized extracellular matrix13, 14, and hydrogels15, 16. 
In recent years, the scientific preference has shifted towards scaffolds synthesized using 
natural materials given their biodegradable and biocompatible properties, emulating closely 
the myocardial microenvironment. Specifically, medium-chain length polyhydroxyalkanoates 
(MCL-PHA) have generated great interest over recent years as functional materials in cardiac 
tissue engineering, with biodegradable, biocompatible, and synthetically tunable physical 
properties17, including flexibility, crystallinity, melting point, and glass transition 
temperatures18. Induced porosity and functionalization of these materials with growth factors 
and active peptide molecules (without and with electrospun blend fibers) has also led to the 
fabrication of cardiac patches with excellent morphological properties, and upregulation of 
cues from the innate matrix structure, thereby promoting enhanced SC (endothelial, inducible 
pluripotent) adhesion and proliferation17, 19. Furthermore, MCL-PHA patches have been 
shown to exhibit similar mechanical properties to myocardial muscle, with a flexibility and 
rigidity that can sustain the cyclic strain patterns developed during the contractile-relaxation 
parts of the cardiac cycle, over prolonged periods that span multiple weeks19. In addition, 
these polymers exhibit degradation by surface erosion, leading to the maintenance of the 
scaffold’s structure for a longer period of time, and hence provide better support functionality. 
Overall, MCL-PHAs are versatile, biocompatible, biodegradable, sustainable, display 
thermoplastic and elastomeric properties, and have predictable mechanical and physical 
characteristics20. They can be mass produced using controlled fermentations21, and their 
biodegradation products are much less acidic (with hydroxyalkanoic acids as the main 
5degradation byproducts) as compared to those of PLLA and PLGA, thereby leading to less 
severe inflammatory responses. However, MCL-PHAa are associated with high production 
costs.
In comparison to MCL-PHAs, synthetic materials–such as poly(L-lactic acid) [PLLA]22 are 
readily available and are associated with well-established processing conditions, however, 
PLLA films are much stiffer than MCL-PHAs and exhibit poorer degradation responses (bulk 
erosion)19, ultimately causing plastic deformation and failure during long-term exposure to 
cyclic strain17. Additionally, PLLA degradation products are acidic in nature, which ultimately 
leads to inflammation and to other undesirable reactions23.
Polycaprolactone (PCL)24 is an elastomeric synthetic polymer that is adaptable, versatile, 
produced in large scale, is associated with precise synthetic control using easily accessible 
materials, prolonged degradation time25, 26, has good miscibility with various polymers, and 
possesses good and predictable mechanical and physical characteristics, often used in load-
bearing tissues to enhance stiffness25, although associated with very low glass transition and 
melting temperatures27.
Despite these advantages, PCL is a non-sustainable polymer, and its production methods 
include solvent- and catalyst-based synthesis. In addition, PCL does not exhibit structural 
variability, and consequently, the resulting range of material properties exhibited by MCL-
PHAs. 
In view of these facts, polymeric MCL-PHA/PCL blends were used in this work to overcome 
the limitations of each of these polymer families, allowing the alteration of the mechanical 
properties of PCL, thereby enhancing the processability of the combined polymer product. 
Despite the existence of prior published work on MCL-PHA/PCL blends28-32, 25, 26, the reported 
compositions, aging, testing, and targeted applications have been distinctly different from this 
work, and they have not been previously used for cardiac tissue engineering applications in 
either unseeded or seeded forms.
Correspondingly, in this effort, we aimed to synthesize MCL-PHA/PCL blend scaffold 
compositions seeded for the first time with cardiac progenitor cells (CPCs) enhancing the 
elicited benefits by capitalizing on the advantages of each material class.
Critical to the successful administration and controlled release of SCs by the scaffold is our 
ability to monitor them noninvasively, particularly in a temporal manner33. Even though 
biolluminescence imaging (BLI) using reporter genes (such as luciferase) has allowed real-
time, in vivo monitoring of viable SCs implanted on scaffolds34, however, the spatial 
localization of the scaffold and its degradability pattern are not easily discernible. 
In this work, we propose the use of novel, functional biodegradable, biocompatible 
natural/synthetic polymer blend scaffolds (comprised of MCL-PHA and PCL) to: a) benefit 
from the material properties of natural and synthetic polymers; b) achieve controlled delivery 
of homologous CPCs—previously shown to elicit beneficial functional effects (in the chronic 
phase) following acute, reperfused myocardial infarction (MI), in preclinical6 and clinical 
studies4—thereby aiming to increase retention of delivered cells to the murine myocardium, c) 
6extend the temporal window over which the release of labeled CPCs is achieved compared to 
traditional direct injection techniques35, and d) use 19F MRI/MRS to noninvasively detect, and 
monitor the cells temporally. 
The choice of the blend material underlies one of the important novelties of this work, given 
the increased ability of structural control in terms of its elastomeric nature and mechanical 
properties, the increased glass transition temperatures compared to neat PCL, and its 
potential to integrate with the myocardial network and be conjugated with bioactive 
molecules, such as vascular endothelial growth factor (VEGF) and Arg-Gly-Asp (RGD)/Tyr-
Lle-Gly-Ser-Arg (YIGSR) peptides to further increase cellular attachment, viability, and 
proliferation17, 19. Another novelty relates to the visualization and monitoring of the repair 
process using 19F MRI. The latter aim is pursued in a physiological model, despite the 
challenges of the low seeding density, cell dispersion, as these are governed by the small 
size of the murine heart, stringent anatomical limitations regarding the scaffold’s placement, 
the endogenous hypoxic conditions, and the temporally dependent migration/dispersion of 
cells within the murine epicardium/mesocardium.   
2. Experimental Procedures
2.1 Production of Poly-3-hydroxyalkanoates (PHAs) 
2.1.1 Production of Medium Chain Length Polyhydroxyalkanoates
MCL-PHAs were produced by Pseudomonas mendocina CH50 using glucose as the sole 
carbon source under a nitrogen limiting conditions36. Batch fermentation was carried out in a 
15 L bioreactor with an operating fermenter volume of 10 L. MCL-PHA production was 
completed in three stages:
a. Preparation of inoculum: A single colony of P. mendocina CH50 was used to inoculate 
sterile nutrient broth. The broth was incubated at 30oC, at 200 revolutions per minute (rpm) for 
16 h. 
b. Preparation of second stage seed culture: The inoculum prepared at the first stage was 
used to inoculate a second stage mineral salt medium with glucose as the carbon source. It 
was incubated at 30oC, at 200 rpm for 24 h. 
c. Preparation and inoculation of production stage media: Prior to the inoculation of the 
production media, the fermenter was sterilized at 121oC for 30 min. The sterile mixture of 
mineral salt medium (MSM), glucose, magnesium sulphate, and trace element solution, was 
aseptically added to the fermenter. The second stage seed culture was used to inoculate the 
production media. The culture was grown for a period of 48 h at 30oC and at 200 rpm. 
2.1.2 Extraction of MCL-PHA
7The biomass was recovered by centrifuging the fermented cultures at a speed of 4600 rpm 
for approximately 45 min. The obtained biomass was lyophilized prior to extraction. MCL-PHA 
was extracted using the two-stage soxhlet extraction method. The powdered biomass was 
refluxed in methanol for 24 h to remove the impurities. The polymer was then extracted in 
chloroform for another 24 h. The solution was concentrated using a rotary vacuum evaporator 




Fourier Transform Infrared Spectroscopy (FTIR): FTIR analysis was also conducted using a 
Perkin-Elmer Spectrum Two Spectrophotometer, as described earlier17. 
Nuclear Magnetic Resonance (NMR): NMR was conducted on a 16.4T (700 MHz), high-field 
spectrometer (Bruker, Billerica, MA, USA) at University College, London. Samples were 
prepared in accordance to standard methodological procedures, as reported earlier36, 37. 
2.2.2 Thermal Characterisation
Thermal properties of the polymer, such as the melting temperature (Tm), and the glass 
transition temperature (Tg), were determined using a differential scanning calorimetry system 
(DSC, Model DSC 214, Polyma, Netzsch, Germany), equipped with an intra-cooler IC70 
cooling system. A polymer sample (5 mg) was heated from –70 to 170oC at a heating rate of 
10oC per minute over two successive heating-cooling cycles. The analysis was completed at 
the end of two heating cycles. DSC thermograms were analyzed using the Proteus 7.0 
software.
2.2.3 Molecular Weight Analysis
The number average molecular weight, (Mn), and the weight average molecular weight, (Mw) 
of the polymer were determined using gel permeation chromatography (GPC, Model 1260 
Infinity GPC, Agilent Technologies). The polymer solution (2 mg/mL) was introduced into the 
GPC system at a flow rate of 1 mL/min. The system was equipped with a 5 μm PLgel MIXED-
C (300×7.5 mm) column calibrated using narrow molecular weight polystyrene standards from 
162 Da to 15 kDa. The eluted polymer was detected with a refractive index detector. The data 
were analyzed using the Agilent GPC/SEC software.
2.3 Scaffold Synthesis and Characterization 
MCL-PHA films were prepared using the solvent casting method38. Nonporous MCL-PHA 
films were prepared by dissolving the polymer (0.5 g) in chloroform (10 mL). The MCL-PHA 
solution was poured into a glass petri dish and was allowed to dry in a closed chamber. 
Polymer blends were prepared by dissolving 0.5 g of polymer with 0.26 g of PCL (Sigma-
Aldrich, UK).
8In order to prepare porous films, 1.7 g of sodium chloride particles of particular sizes (75, 100 
μm) were used as porogens. These were added into the polymer solution, mixed, and then 
poured into glass petri dishes. Upon drying, these films were immersed in water to allow 
sodium chloride to leach out of the films39, 40. These films were dried in a closed chamber.
The basis for the ultimate choice of the 95/5 wt% MCL-PHA/PCL blend composition is 
attributed to the outcomes obtained from empirical optimization tests (at different blend 
compositions and porosities), and is based on previous work on PHA-based blends in relation 
to nerve tissue engineering using 95/5 wt% and 75/25 wt% MCL-PHA/PCL blends41.
2.3.1 Mechanical Characterization
Mechanical properties of the porous and nonporous films were tested using an Instron tensile 
testing system (Instron, Model 5942 Testing Systems, Buckinghamshire, UK). This analysis 
was carried out on solvent cast film strips of specified widths and lengths (n=3, >10 mm in 
length and 5 mm in width). Tensile strength, elongation at break (%), and Young’s Modulus 
values were determined from the stress–strain curve using the Instron’s analysis package 
(BlueHill 3) or via offline analysis. 
2.3.2 Morphological Properties
Surface properties of the porous and the nonporous films were studied using a JEOL 5610LV 
scanning electron microscope (SEM) (Hertfordshire, UK). MCL-PHA film samples were 
mounted on conducting aluminium stubs, and were coated with gold-platinum using an 
Emitech-K550 gold sputtering coater (Ashford, Kent, UK) for approximately 2 min before they 
were imaged using the SEM. The images were acquired using an acceleration voltage of 10 
kV at a 10 cm working distance at the Eastman Dental Institute, University College, London.
2.3.3 Hydrophobicity-Contact Angle Measurements
Contact angle (θ) measurements were performed using a KSV Cam 200 optical contact angle 
measurement system (KSV Instruments Ltd.) on both porous as well as nonporous MCL-PHA 
films to determine their wettability. Distilled water and cell media (200 μL) were placed on the 
surface of the film sample using a gas tight syringe. Ten images of the water/media droplets 
dispersing on the surface of the film sample were captured within a frame interval of 1 s. The 
analyses of the images were performed using the KSV Cam software. All work was 
completed at the Eastman Dental Institute, University College, London.
2.4 Cardiac Progenitor Stem Cells
2.4.1 Isolation of Cardiac Progenitor Cells, Labeling, and Scaffold Seeding
Cell Isolation: CPCs were isolated from adult, C57BL/6, mouse atria. Specifically, after hearts 
were excised, they were washed, digested with 0.05% trypsin-EDTA, and the tissue explants 
were plated on fibronectin-coated petri dishes. They were expanded in culture as collagenase 
and trypsin digestion cells (CT) in accordance to standard methods described previously42.
9Labeling: Cells were then plated in Iscove's Modified Dulbecco's Medium (IMDM, Thermo 
Fisher Scientific, UK) and incubated in culture with Perfluoro-crown-ether (PFCE)-containing 
fluorescent nanoparticles (NPs) (containing Atto647) (10 mg/mL in 1 million cells)43 and 
FuGENEHD (Promega, Madison, WI, USA) for approximately 24 h before trypsinization, 
isolation, and pelleting. Final cell pellet suspensions containing approximately 1 million cells 
each were maintained in cell media solutions and transferred to Eppendorf volumes 
containing 1.7 mL IMDM. Labeled cells were used to seed the scaffolds for SEM, magnetic 
resonance imaging and spectroscopy (MRI/MRS), and confocal microscopy experiments. 
Cell Seeding: Cells (unlabelled or labeled) were seeded on scaffolds overnight after isolation 
and pelleting. The seeding density was 20k/scaffold for confocal-epifluorescence imaging, 
and 300-500k/scaffold for in vitro MRI studies, with scaffolds cut at sizes spanning 2-8×2-8 
mm2. Scaffolds were subsequently washed with PBS (1:7 v/v), and fixed cells were seeded 
(in 2% paraformaldehyde (PFA) solution), while live cells were seeded in IMDM media. 
Scaffolds were subsequently prepared for high-content, confocal imaging, SEM, or for MRS.
In vivo scaffolds were cut into a trapezoidal shape (the smaller side was implanted towards 
the apex) with a size of 2×5 mm2, with a height of 4 mm. The optimal seeding density was 
found to be 300-350k cells in 100 μm porous scaffolds (the ratio of the final number of cells to 
the number of the originally seeded cells was ~0.6). This estimate was based on in-vitro 
experiments where Trypan blue cell counts were conducted upon initial seeding/incubation, 
and corresponding counts of the freely floating cells in the IMDM media after the incubation 
period after the transfer of the scaffold in a new Eppendorf tube with fresh media. To 
maximize the cell density, a double-layered scaffold was implanted in a second mouse and 
studied in vivo, as reported below. The double-layered scaffold was composed of two single 
layer scaffolds that were glued at their four corners using surgical glue (Histoacryl, Braun 
Surgical S.A., Spain).
2.5 In Vitro Cell Adhesion and Proliferation Studies of Seeded Scaffolds 
2.5.1 High-Content Microscopy-Epifluorescence Imaging
Epifluorescence Imaging: Live cells were stained with Calcein (CellTrace™ Calcein Red-
Orange, ThermoFisher Scientific, UK) for high-content imaging, and plated in 96-well plates. 
Cells (n=3, ~20-50 k cells/well) were maintained in culture up to 7 d (D), and a time course 
study (D1-D7) of live cells was conducted to assess cell survival (Calcein) using a high-
content imaging system (Operetta, Perkin-Elmer, UK) (results not shown). 
 
Label Detection - Confocal microscopy 
Fluorescent NPs were imaged [excitation wavelengths: λgreen=488 nm, λred=633 nm, emission 
ranges: 500-550 nm (green) and 650-700 nm (red)] using phase contrast, and red/green 
excitations in control cell samples, and in samples with and without FuGENE, using a Leica 
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TCS SP8 confocal microscope (Leica-Microsystems, Mainhem, UK) with HyD detectors, and 
an objective with numerical aperture (NA)=1.4, 63X. 
2.6 In Vitro, Post-mortem, and In Vivo MRI/MRS
2.6.1 Animal Ethics
All experimental procedures involving animals were approved by the Home Office (UK) and 
were in accordance to the guidelines under The Animals (Scientific Procedures) Act, 1986, 
the European Animal Research Directive 2010/63/EU, and with local institutional guidelines.
2.6.2 Radiofrequency Coils
For MRI studies, a 4×4 cm2 single-turn, transmit/receive butterfly coil (implemented on a 28 
mm diameter plastic former) [in vitro/post-mortem/in vivo studies], and a 5 (diameter)×8 
(length) mm2 solenoid coil [in vitro studies], were fabricated in-house using flexible copper 
laminate sheaths, tuned, and matched to the 19F resonant frequency at 375.8 MHz. The 
broad frequency response of the coil allowed intermittent imaging on the 1H and 19F nuclei.
2.6.3 MRI/MRS of Nonporous and Porous Scaffolds
In vitro studies: Unseeded and seeded scaffolds were maintained in IMDM media and placed 
in 0.2-0.7 mL Eppendorf tubes. 1H and 19F MRI/MRS were then conducted. For post-mortem 
studies, 1H/19F MRI were performed on hearts with control (unseeded) and labelled (seeded) 
scaffolds positioned using fibrin glue (Baxter, UK) on the anterior epicardial surfaces. 
In vivo studies: Healthy mice were anesthetized and maintained using 1.5% isoflurane. They 
were then intubated and underwent a lateral thoracotomy. Scaffolds were positioned on the 
anterior myocardium using histoacryl surgical glue (B. Braun Surgical S.A., Spain). Mice were 
recovered, monitored for adequate post-surgical recovery, and transferred to MRI for imaging. 
They were then re-anesthetized in accordance to standard imaging protocols. Imaging 
parameters for all MRI/MRS acquisitions are listed below.
a) In Vitro Studies 1H MRI (unseeded/seeded scaffolds): 1H MRI was completed with two-
dimensional (2D) segmented k-space, double-gated spoiled gradient echo (SPGR), and 
three-dimensional (3D) ungated sequences. 
b) 19F-MRI/MRS: Work was performed on a 9.4T Varian scanner. 19F spectra were acquired 
using nonlocalized acquisitions (ungated and gated for in vivo scans) with the following 
parameters: repetition time (TR)=800-1000 ms, number of excitations (NEX)=64 or 256, 512 
points, bandwidth (BW)=20 kHz, receiver gain (RG)=30.
c) In Vitro Studies 19F MRI (unseeded/seeded scaffolds): Correspondingly, the 19F MRI 
acquisitions (SPGR, steady state free precession (SSFP)) were: TR=8.3 ms, TE=4.17 ms, flip 
11
angle=50°, NEX=1024, matrix=32×32, ST=10 and 40 mm, BW=4 kHz, RG=30, total 
acquisition time=4.3 min.
d) Post-mortem Studies (unseeded/seeded and labelled scaffolds): The 2D 1H MRI 
acquisition parameters were: TR=2.73 or 3.13 ms, TE=1.58 ms, flip angle=50°, NEX=32, 
matrix=128×128. FOV=40x40 mm2, ST=1 mm, BW=100 kHz, pw=1500 μs (total acquisition 
time = 12.8 s). The 3D 1H MRI acquisition parameters were: TR=2.63 ms or 2.73 ms, 
TE=1.33 or 1.38 ms, flip angle=20°, NEX=4, matrix=128×128×128, FOV=40×40×40 mm3, 
BW=100 kHz, total acquisition time=2.5 min. 
The corresponding 19F acquisition parameters were: TR=8.31 ms, TE=4.17 ms, flip 
angle=50°, NEX=796, matrix=32×32, ST=5 mm, BW=4 kHz, total acquisition time=3.31 min. 
19F MRS was acquired with nonselective excitation using TR=800 ms, NEX=256, 512 points, 
BW=20 kHz, RG=30. 
e) In Vivo Murine Studies: 3D ungated scans were acquired using the following imaging 
parameters: TR=3 ms, TE=1.68 ms, flip angle=30°, NEX=4, matrix=128×128×128, 
FOV=40×40×40 mm2, BW=100 kHz, total acquisition time =5 min.
2.7 Histology
2.7.1 Cellular Retention
Post-mortem histological evaluation was performed at D1 and D7 post-scaffold implantation 
to assess CPC retention. Mice were euthanized by cervical dislocation under general 
anesthesia and the hearts excised. The hearts were then dehydrated and fixed (either in a 
15% sucrose, 0.4% PFA solution, or in a 4% PFA solution) after which they were embedded 
in paraffin and stored (at -80oC or room temperature). Serial transverse paraffin sections of 
10-17 μm were cut, from base to apex for histological staining using a nuclear stain 4', 6-
diamidino-2-phenylindole (DAPI). Imaging and analyses were performed on a bright-field 
optical and on a confocal microscope (nuclear (DAPI), label (Atto647)). 
2.8 Image Processing
2.8.1 Image and Spectral Analyses
Low-resolution 19F MR images were imported and interpolated in ImageJ (NIH, Bethesda, 
USA) using bicubic splines to match the 1H matrix size. Thoracic muscle 1H and 19F MRI were 
overlaid in ImageJ (opacity=40-70%). In vitro and in vivo spectra were read and processed in 
CSX (P. Barker-Kennedy Krieger Institute, Johns Hopkins USA) and using the interactive 
data language software (IDL, Harris Geospatial, USA). Signal and signal-to-noise ratio (SNR) 
values were estimated using standard methodologies44. 
High field polymer spectral processing was conducted using the Mnova software package 
(v12, Mestrelab Research, S.L., A Coruna, Spain). The chemical shifts were referenced 
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against the residual solvent signals at 7.26 ppm and 77.0 ppm for the 1H and 13C spectra, 
respectively.
2.9 Statistical Analyses
All results are reported as mean ± standard deviation (SD). Paired and unpaired, two-tailed 
Student’s t-tests, were also used (XLSTAT, Addinsoft, New York) for mean comparisons 
(α=5%).
3. Results
3.1 Production of Poly(-3-hydroxyalkanoates) and physical characterization
The polymer was produced by the fermentation of P. mendocina CH50, purified, and 
structurally characterized, as previously described36 (Figure 1). The concentration of the 
obtained biomass at the end of fermentation was 1.5 g/L. The final PHA concentration was 
0.52 g/L. 
3.1.1 FTIR and NMR
The polymer was identified to be MCL-PHA using FTIR. The two characteristic peaks of MCL-
PHAs (1726.2 cm-1, indicative of the ester carbonyl bond and 1160.0 cm-1, indicative of C-O 
stretching) were present in the elicited FTIR spectrum. Final confirmation of the polymeric 
structure was carried out using 13C and 1H Nuclear Magnetic Resonance (NMR) spectroscopy 
(Figure 1 and Table 1). The observed 1H NMR peak area ratios for the MCL-PHA were 
2:1:2:8:3 (a: b: c: d, d*: e, e*), which exactly corresponded to the expected ratios from the 
structure, as shown in Figure 1B. The elicited ratio value of 8 obtained for the 1Hs (annotated 
as d, d*) is the average of 6 and 10, that is, the number of protons in each monomeric unit 
type. In the case of the MCL-PHA/PCL blend, the polymeric peak ratios matched those of the 
pure MCL-PHA polymer. Hence, the MCL-PHA related peak area ratios were 2:1:2:8:3 (a: b: 
c: d, d*: e, e*), while those for the PCL were 1:2:1:1 (^a: ^b: ^c: ^d), as shown in Figure 1C.
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Figure 1: Synthetic and chemical characteristics of polymer: (A) General chemical 
structure of polyhydroxyalkanoates (x=1, 2, 3; n=100-30000; R1, R2=alkyl groups; C1-C13 
units). (B-E) NMR spectra of the MCL-PHA and MCL-PHA/PCL blend.  (F, G) Corresponding 
FTIR spectra for MCL-PHA and MCL-PHA/PCL blend depicting the ester carbonyl bond and 
C-O stretching peaks. Only the characteristic peaks for PHAs and polycaprolactone are 
annotated in FTIR spectra45, 46. 
Table 1: Chemical shifts (δ) for (A) 1H NMR peaks and corresponding chemical shifts for (B) 









CH 5.20 (b, multiplet) 4.1 (^a, triplet adjacent to carbonyl group)
CH2 2.50 (a, eightfold peak) 2.30 (^d, triplet)
CH2 1.58 (c, multiplet) 1.65 (^b, eightfold peak)
Other CH2 1.25 (d, d*, multiplet) 1.40 (^c, multiplet)




3-hydroxyoctanoate 3- hydroxydecanoate Caprolactone
173.0 - - ^C6
170.0 C1 C1 -
70.0 C3 C3 -
64.0 - - ^C1
40.0 C2 C2 -
34.0 C4 *C4 ^C5
32.0 C6 *C8 -
30.0 - *C6, *C7 -
28.0 - - ^C2
25.0 C5 *C5 ^C3
24.0 - - ^C4
23.0 C7 *C9 -
14.0 C8 *C10 -
3.1.2 Thermal Properties
DSC was used to determine the thermal properties of the synthesized materials (Table 2). All 
thermograms showed the presence of two or more peaks corresponding to the melting and 
glass transition temperatures. Tg values for the MCL-PHA scaffolds (nonporous [n=4] and 
porous (75 [n=1]/100 μm [n=4]) at 100%) were -44.5/-44.0/-44.5oC, while the corresponding 
values for the MCL-PHA/PCL blends (with PCL at 95/5%) were -48.2 (n=4)/-44.2 (n=1)/-
46.5oC (n=3). The corresponding Tm values were 52.1 (n=4)/53.2 (n=1)/53.6oC (n=4) (100% 
composition) and 50.4 and 58.3/52.8 and 56.0/51.9 and 59.4oC for the PCL blends. Two 
values are reported for the blends corresponding to the two distinct peaks elicited in the PCL 
blend thermograms. 





MCL-PHA (100%) Nonporous [n=4] -44.5±1.6 52.1±0.4
MCL-PHA/PCL (95/5%) Nonporous [n=4] -48.2±0.5 50.4±0.1/58.3±0.1a
MCL-PHA (100%) Porous (100 μm) [n=4] -44.5±1.9 53.6±0.4
MCL-PHA/PCL (95/5%) Porous (100 μm) 
[n=3]
-46.5±1.1 51.9±0.1/59.4±0.3a
aReported values correspond to the separate peaks of the MCL-PHA/PCL thermograms
3.1.3 Mechanical Properties
2D patches [nonporous and porous (75 and 100 μm porosity)] were fabricated using the 
solvent casting technique. Controlled porosity is a critical morphological characteristic for 
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biocompatible scaffolds for cell adhesion and growth. Therefore, porous patches were 
fabricated. The porosity was optimized based on the mechanical properties of the 
synthesized scaffolds (75, 100 μm), using tensile testing (Figure 2, Table 2). 
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Figure 2: Mechanical characteristics of synthesized scaffolds: Histogram plots of (A) 
ultimate tensile strength (MPa), (B) elongation at break (%), and (C) Young’s Modulus (MPa) 
for the nonporous (n=4), porous (75 μm [n=3], and 100 μm [n=7]) scaffolds. Results represent 
mean±sd values over 3-7 independent tests (Table 3).









MCL-PHA (100%) Nonporous 7.83 507.25 4.63
MCL-PHA/PCL (95/5%) Nonporous 7.40 526.50 4.65
MCL-PHA (100%) Porous (75 μm) 2.38 528.00 0.68
MCL-PHA (100%) Porous (100 μm) 1.31 212.50 1.92
MCL-PHA/PCL (95/5%) Porous (75 μm) 2.34 604.33 0.72
MCL-PHA/PCL (95/5%) Porous (100 μm) 0.91 206.00 1.46
3.2 Surface Characterization
The surface characteristics of the neat and porous scaffolds were quantified in terms of 
wettability and imaged using SEM. Surface morphology and microstructural features of the 
optimized porous scaffolds were visualized in cases of seeded scaffolds with CPCs using 
SEM, as shown in Figure 3. 
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Figure 3: Surface morphology of porous scaffolds: Morphological characterization of 
synthesized (A, D) porous (MCL-PHA, MCL-PHA/PCL) scaffolds ((A, C) non-seeded, and (B, 
D) seeded with cardiac progenitor CT GFP-ve cells) using scanning electron microscopy. 
Indicative results are shown from the 75 μm porous scaffolds.
Surface wettability was quantified only for the neat scaffolds using water and IMDM media 
with a drop shape analyzer. The mean water contact angles for the nonporous scaffolds 
(MCL-PHA vs. MCL-PHA/PCL) were 90.0±11.6°/80.7±4.2° (water), and 88.8±6.7°/72.0±2.5° 
(IMDM), as shown in Figure 4. The contact angles were significantly lower higher in the H2O 
vs. the IMDM cases (MCL-PHA: p<0.013, PCL: p<0.015). Significantly decreased mean 
contact angles were also observed in the MCL-PHA/PCL vs. MCL-PHA samples in the case 
of IMDM tests (p<0.004), indicative of increased hydrophilicity.
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Figure 4: Contact angle measurements in synthesized scaffolds: Mean contact angles 
(mean±sd) over 6-11 independent measurements for three different samples of each of the 
synthesized scaffolds (neat MCL-PHA, and MCL-PHA/PCL blend at a composition of 95/5 
wt%) using water and IMDM media.
3.3 Cardiomyocyte Cytocompatibility Studies
3.3.1 CPC Cell Density
The biocompatibility, cell surface adherence characteristics, and cell seeding density of the 
optimal porous scaffolds (with a porosity of 100 μm) were assessed using high-content 
epifluorescent imaging in vitro, using unlabeled and 19F FuGENE-labeled cells (50-70k). The 
first set of experimental tests assessed the differences of cell adherences on the two types of 
the porous scaffolds having an optimal porosity of 100 μm. Elicited results are summarized in 
Figure 5 (A-B). Figure 5 clearly shows the increased cell adherence (and correspondingly 
increased viable cell density) in the MCL-PHA/PCL (Figure 5B) compared to the MCL-PHA 
neat scaffold (Figure 5, B). Quantification of the total number of viable cells was challenging 
given the 3D porous structure of the scaffold, and its optical scattering characteristics.  
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Figure 5: Comparison of in vitro CPC attachment on the two types of synthesized 
scaffolds: High-content (epifluorescent) imaging of porous MCL-PHA scaffolds (with a 100 
μm porosity) seeded with (A) unlabelled (~50-70k cells) and CT cells [cytoplasmic Calcein 
stain (orange), nuclear Hoechst stain (blue)]. Results indicate the lower affinity of porous 
MCL-PHA scaffolds for unlabeled cardiac progenitor stem cells. (B) Increased cell density is 
observed for the porous MCL-PHA/PCL scaffold.
3.4 Noninvasive, Temporal Monitoring of Scaffolds using 19F MRS/MRI 
3.4.1 In Vitro, Post-mortem, and In Vivo Scaffold Characterization 
Of increased interest are the MRS/MRI results from in vitro tests of the scaffold with optimal 
porosity (100 μm), summarized in Figures 6 and 7, over a temporal period of 9 days (D1-D9) 
following seeding with FUGENE-labeled cells. Constancy of cell retention is justified in Figure 
6 by the 25% integrated MRS area difference between D1 and D3. The cell density 
decreased to 44% at D6 and to 30% at D9. MRI also achieved visualization and clear 
delineation of the scaffolds using both 1H and 19F MRI, as indicated in Figure 7. Indicative is 
the decreased signal (and SNR) responses at D6 compared to earlier days (Figure 7 G-I).
Figure 6: Temporal, in vitro MRS characterization of persistence of CPC attachment on 
the optimal type of porous scaffolds: Magnetic resonance 19F spectra (MRS) of MCL-
PHA/PCL (100 μm, 95/5%) scaffolds that were initially seeded with using 300k FuGENE-
labeled CT cells each at (A-D) days 1 (D1), D3, D6, and D9. 
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Figure 7: In vitro MR visualization and temporal monitoring of CPC seeded porous 
scaffolds: (A-C) Indicative axial (A) and coronal/sagittal (B, C) axis 1H MRI views of a 75 μm 
porous MCL-PHA/PCL 95/5 wt% blend scaffold (arrows) showing in vitro detectability 
(samples immersed in IMDM media in 0.7 mL Eppendorf tubes). (D-F) Corresponding axis 
and coronal/sagittal views of a 100 μm porous scaffold in vitro. (G, I) 19F MRI of seeded 
scaffold (MCL-PHA/PCL 95/5 wt% blend) with labeled cells. Axial views have a slice 
thickness of (G-I) 10 mm at D1, D3, and D6.
The seeded scaffolds were successfully tested in the post-mortem mouse using both 19F 
MRS/MRI, as shown in Figure 8 (A-D). Results indicate responses at the first day following 
scaffold implantation. More interesting are the elicited results from the in vivo tests conducted 
in two C57BL/6 mice, indicating the ability of 19F MRS to detect and track the labeled, seeded 
cells, within a week following initial implantation (Figure 8E-H). The two peaks on the left-
most part of the PFCE-NPs represent the accumulated isoflurane peaks, as reported earlier48. 
The double-layered scaffold was also clearly and distinctly identified in 1H MRI at D1 and D7 
(the detected 19F area doubled compared to the single-layered scaffold), as shown in Figures 
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8G, H. The single-layered scaffold was not visible using 19F MRI as a result of the low 
seeding density (<300k at D1) [ultimately dependent on the scaffold’s size in the case of the 
mouse], and the heterogeneous distribution of seeded cells within the scaffold, an effect that 
worsens owing to the rhythmic and cyclical contraction-relaxation pattern of the mouse heart 
at rates exceeding 350 beats per minute. 
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Figure 8: In vivo MR visualization and monitoring of signal responses from CPC 
seeded scaffolds: In vivo 1H MRI of seeded scaffolds (with labelled CT cells) on the antero-
lateral murine myocardium of normal C57BL/6 mice at day 1 (D1) from (A) single-layered and 
(B) double-layered porous MCL-PHA/PCL 95.5 wt% (100 μm) scaffolds seeded with 
FuGENE-labeled CT cells. (C) In vitro axial 19F MRI of the single-layered scaffold. (D) In vitro 
comparison of single- and double-layered scaffolds using 19F MRS, and (E-H) corresponding 
ungated 19F MRS from the in vivo mouse (E, F) (single-layered scaffold), and (G, H) double-
layered scaffold at D1 and D7. (I, J) Two separate axial views of the fused 1H-19F MRI of the 
double-layered scaffold at D1 and D7.    
3.5 Histological characterization of implanted scaffolds  
Figure 9 shows a histological short-axis, mid-apical view of the post-mortem heart indicating 
the sites of cellular migration and retention of CPCs within the myocardium and the scaffold. 
Also shown are the existing cellular entities at the interface of the scaffold and myocardium, 
as identified using bright field and confocal imaging (Atto647, DAPI). 
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Figure 9: Histological assessment of single- and double-layered porous scaffolds 
seeded with CPCs: (A) Histological short-axis, mid-apical view of a fixed heart indicating the 
sites of scaffold (single layer) attachment, seeded scaffold cells, and cell retention of CPCs in 
the neighbouring myocardium. (B-D) Arrows in the middle and right sides of the subfigures 
indicate the locations of the scaffold and the scaffold-myocardial interface. (E-G) Black arrows 
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indicate the locations of detected cells (CPCs and red blood cells). (H-P) Shown also are 
fluorescent views (nuclear (DAPI), and label (Atto) presented in grayscale, and fused shown 
in color [Atto-red, DAPI-blue]), indicating CPC retention (H, K, N) within the scaffold and 
myocardium (white arrows). (Q-V) Corresponding histological and fluorescent views of the 
double-layered scaffold (shown in grayscale). Indicative is the increased number of cells 
within the myocardium compared to the single-layered case. Bright field images have been 
pseudocolored in different instances for better visualization.
4. Discussion
In this work, a novel, polymeric MCL-PHA/PCL blend material has been proposed for use as 
the substrate of a controlled delivery patch/scaffold for controlled SC release in cardiac tissue 
applications16, 36. Both MCL-PHA and MCL-PHA/PCL polymer types have been studied 
previously and have shown exceptional attributes to adhesion and cell proliferation for 
SCs16, 18, 24. In particular, MCL-PHAs have exhibited increased elastomeric responses, low 
crystallinity, low tensile strength, low melting points, and high elongations at break, and have 
been extensively studied in various applications to-date49-51. However, blend MCL-PHA/PCL 
compositions have not been explored previously for their suitability and responses in 
applications in vivo or for temporal imaging with CPCs. We show improved properties from 
synthesized scaffolds, capitalizing on the merits of each material class, as discussed below. 
Chemical, Thermal, and Morphological Characteristics
The signaling interplay between the seeded CPCs on scaffolds and the local 
microenvironment have been shown to be deterministic for the cell fate, including migration, 
proliferation, differentiation, apoptosis, and/or homing/engraftment6. Correspondingly, the 
physical, morphological, and functional characteristics are deterministic for such responses.
Furthermore, the biocompatibility and degradability are essential to silence 
inflammatory/infectious responses, especially in cardiac disease. The scaffold’s long-term 
stress/strain and thermoplastic responses are also critical in view of the cardiac cyclic activity.
DSC was used to assess the polymer’s thermal properties, yielding (as previously shown) two 
distinct peaks corresponding to the Tg and Tm values observed within the ranges of 44–47oC 
and 51–56oC, respectively. Low glass transition and melting temperatures have a direct 
elastomeric impact on the material’s response and are typical for MCL-PHA. Nevertheless, 
similar thermal properties were elicited for MCL-PHA and MCL-PHA/PCL blends that are 
most suitable for the proposed in vivo scaffold applications.
Porosity is also invariably linked with seeding density, and the ability of cells to inflitrate/cross-
link, migrate, and for cell ingrowth (through maximization of the surface area and active 
binding sites). Despite pore size disparity, all samples (neat and blends at 95/5% 
compositions) were similar in pore and cellular morphology, thus confirming batch 
reproducibility.
26
A pore size of 100 μm was chosen, which is larger than the sizes of cells contained in the 
heterogeneous mixture of CPCs (endothelial, fibroblasts, innate cardiac SCs, spanning a size 
range of approximately 10-40 μm (mean pore size (±sd)=19.5±8.8 μm) in each spatial 
dimension. The porogen concentration used was optimal, in accordance to prior published 
work17. Smaller pore sizes are prohibitive for cellular seeding and permeation, while large 
pore sizes may prove detrimental to the scaffold’s cell retention capacity. 
Mechanical Characteristics
The scaffold’s rigidity/flexibility is of upmost importance for eliciting proper functional 
responses (support for adhesion of seeded cells) and attaining a proper coupling constant52 
with the injured myocardium. Correspondingly, the ability to control, study, and quantify its 
mechanical characteristics is critical, and these attributes have been extensively investigated 
herein. 
The constitutive law manifested in terms of the stress–strain response of the material is fully 
deterministic for its mechanical response under all operational conditions. To this effect, 
stress–strain was quantified for these membranes at room temperatures. No experimentation 
was conducted using membrane samples immersed in buffer solutions, although prior work 
has shown additional beneficial effects17. The decrease of the Young’s Modulus values for the 
nonporous versus the porous counterparts was anticipated. Of importance is the noted 
decreasing trend for these values in the case of the blend scaffolds compared to the MCL-
PHA counterparts as reported previously53, indicative of a decreased stiffness. The 
documented disparity in the trend of Young’s modulus values for scaffolds with targeted 
porosities of 75 μm and 100 μm is attributed to the actual pore size disparity (from targeted 
values) and increased pore size variability in these scaffolds. It is thus likely that the pore 
distributions in the two cases at the spatial scale of uniaxial tensile testing are similar.
The elongation at break and tensile strength were comparable for the neat and porous 
scaffolds, but significantly smaller in value compared to PCL constructs54, and significantly 
higher than the reported ranges for human myocardium (100-300% for the elongation at 
break, and 3-15 kPa for tensile strength)55, 56. The achieved Young’s Modulus values of the 
optimized (unseeded) porous scaffolds are high compared to targeted values of murine and 
human myocardium in the range of 0.02–0.5 MPa17, 52, 54-56. The stiffness of seeded scaffolds 
is anticipated to be even higher, exacerbating the scaffold-myocardium stiffness difference. 
While such property is fundamental in achieving an appropriate mechanical stiffness gradient 
between the patch and myocardium, the observed Young’s modulus mismatch is not 
envisaged to be deleterious for the proposed applications. We not anticipate that an exact 
match is required for the scaffold to be effective. Instead, we consider the chemical gradient 
(owing to the concentration difference of free, mobile SCs in the scaffold and the endogenous 
pool of SCs in the innate myocardium) to be the most critical factor in facilitating an efficient 
diffusional-migratory SC process, especially in the case of the injured myocardium. 
Reinforcing these arguments is the fact that the stiffness of MI tissue (as previously 
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characterized using atomic force microscopy56) is greater than that of healthy myocardium 
(i.e., the stiffness mismatch is smaller). Correspondingly, the chemical gradient (increased SC 
density in scaffold versus lack of cells, or minimal number of recruited SC cells from the 
endogenous niche pool in MI tissue) is thus expected to be the predominant driving force for 
cell migration.
An additional advantage of the scaffold is that it can act as a passive restraint explant to 
provide mechanical support, or equivalently, act as a ‘passive-assist construct’, to counteract 
the induced stress from the myocardial pressure-overload during remodeling in reperfused 
MI. The beneficial characteristics of the scaffold as a possible passive-assist explant are 
anticipated to be highly effective in the case of MI, whereby the load restraint imposed by the 
attached patch is expected to ameliorate and offset the dilatatory and hypertrophic response 
of the injured myocardium, elicited in the acute (dilation), and chronic MI phases (connective 
tissue deposition and scar formation) that ultimately lead to heart failure. The elongation at 
break and ultimate tensile strength characteristics were also within expected operational limits 
for both healthy and diseased states17, 19. Of increased importance are perhaps the surface 
characteristics of the scaffold, as described next.
Surface Characterization
The material’s roughness and hydrophobicity are critical markers relevant to cellular adhesion 
and proliferation16. The surface roughness of this MCL-PHA was reported previously based 
on light interferometric techniques and measurements17, 19 with a noted increase in the case 
of porous versus neat patches. 
SEM and surface contact analyses revealed that both the neat and non-porous blend films 
had smooth, and regular surfaces, and that the specific cardiac myocytes adhere well on the 
outer surfaces of the non-porous scaffolds. 
Given that the measured contact angles were 90° or less, both material types are considered 
as hydrophilic. As expected, there was an increased surface hydrophilicity with the use of 
IMDM, an effect that is more prominent in the MCL-PHA/PCL blends compared to the MCL-
PHA scaffolds. This is expected as a result of the content of such media in electrolytes and 
other proteins that facilitate surface binding and adhesion. Surface contact angle results 
(IMDM vs. H2O) have also been justified by SEM analyses indicating good outer surface 
adherence of CPCs in both cases (neat and porous). More importantly, increased 
hydrophilicity was documented in the case of neat MCL-PHA/PCL scaffolds compared to their 
MCL-PHA counterparts, confirmed by the excellent CPC attachment and increased retention, 
as shown by confocal microscopy and 19F MRS findings. Further hydrophilicity increases are 
expected from the functionalization of these scaffolds with VEGF and RGD/YIGSR peptides17. 
Novel Functional Response in Cardiac Tissue Engineering
Cell Retention, 19F Temporal Persistence, and Noninvasive Monitoring
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The material has been synthesized to attain optimal characteristics (including pore size, 
actual physical dimensions, biochemical composition) to tailor its physical, chemical, thermal 
characteristics, and to optimize the seeding density of CPCs with fluorinated NPs for 
visualization and temporal tracking using MRS over periods spanning >7-9 days.
The pore size of the scaffold has been chosen to be large enough to accommodate all 
different types of cells contained in the heterogeneous population of the seeded CPCs 
(including primarily innate myocardial, endothelial cells, and fibroblasts), yet being able to 
accommodate other types of cardiac stem cells (e.g., mesenchymal, embryonic, inducible-
pluripotent, and others). 
The scaffold’s seeding density (limited capacity determined by pore size, thickness, and size 
of patch ultimately limited by the murine myocardium) is approximately 350 k cells/scaffold, 
which is at the limit of the capacity of 19F MRI to detect and monitor labeled cells using fast 
imaging with the described imaging methodologies at 9.4T.
Overall, SC retention has been proven, yet the cellular attachment can be further improved 
using VEGF/RGD/YIGSR. Nevertheless, the ability to maintain cells viable over multiple 
weeks is/will continue to be a challenge, as will be the determination on whether the 
increased 19F signal observed at later time periods using the double-layered scaffold is due to 
released NPs from lysed cells within the pouch region between the two layers. 
Temporal-dependent 19F MRI decreases from seeded scaffolds, likely attributed to cell death, 
decreased cell adherence, and increased leaching rates of nonviable and viable cells, need to 
be investigated further. Conclusive confirmation is envisaged to be provided by in vitro 
dead/live assays and post-mortem immunohistochemical assays following in vivo imaging, as 
part of future planned work.
The engraftment also needs to be assessed once the optimal scaffold conditions are attained 
over periods of 1-8 weeks to assess N-cadherin, connexin43, and spatial gap junction 
formation and localization within the intercalated disc58. Although the exact mechanisms 
through which scaffolds exert beneficial effects are still not well understood, it is likely that 
they promote neogenesis and angiogenesis in conjunction with an associated increased SC 
viability and proliferation, amplifying the beneficial paracrine effects. 
Overall, the elicited results from prior and ongoing clinical trials and preclinical studies of 
CPCs and SCs have been promising. Nevertheless, despite the existence of vast prior work 
in this field, important questions still remain, including the optimal choice of cells, growth 
factors, the scaffold’s mechanical coupling and directionality of the explants with respect to 
the injured myocardium58, and the exact timing of its administration after MI in order to elicit 
maximum benefits59. 
Conclusions
We have presented applicability of MCL-PHA/PCL porous blends fabricated as thin films with 
an improved performance compared to MCL-PHAs, capitalizing on the excellent polymeric 
properties of natural MCL-PHA polymers, and the simplified synthetic process relevant to 
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PCLs. We have also demonstrated superior MCL-PHA/PCL scaffold performance compared 
to MCL-PHA scaffolds through experimental comparisons of a) morphological data using 
SEM and b) contact angle measurements indicative of increased hydrophilic responses of the 
blend scaffolds attesting to improved CPC adhesion, c) in vitro confocal microscopy showing 
increased SC proliferative capacity, d) mechanical testing that elicited good overall 
responses, e) improved in vitro NMR retention of seeded SCs, and f) and in vivo applicability 
and MRI visualization of labeled SCs over periods spanning 8 days. The scaffold’s structural 
and morphological characteristics are tunable and could allow maximization of the seeding 
density for easier detection and temporal follow-up using direct 19F MRI/MRS in vivo, 
anticipated to be beneficial to larger animals/humans. The proposed scaffold can be 
potentially modified synthetically to address the induced CPC hypoxic state post-scaffold 
implantation through the controlled delivery of exogenously administered oxygen via the 
scaffold, particularly following MI, as a result of the loss of perfusion pathways and myocardial 
vascular obstruction (MVO) effects. Additionally, conjugation/functionalization of the scaffold 
with angiogenic, vascular growth factors, and peptides, is possible, and is expected to lead to 
even further increases in cellular attachment and proliferation, as evidenced previously in 
MCL-PHA seeded with other SC types17.
Based on this work, and the elicited preclinical outcomes in normal mice in vivo, MCL-
PHA/PCL blends are expected to have tremendous potential as future materials for cardiac 
patch development. A dual approach combining direct injections and controlled delivery of 
CPCs using these scaffolds is expected to maximize potential benefits following infarction. 
For translational purposes, refinement of the synthetic method of patch production is also 
envisaged, whereby the automation of the processing of polymeric synthesis and its direct, in 
situ injection can be implemented in accordance to recently published studies60, 61. Studies on 
their suitability and effects on MI are ongoing.
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